Holen Sie sich die Stockscreener-App
9.31
6.64%
0.58
Vorhandelsmarkt:
9.10
-0.21
-2.26%
Schlusskurs vom Vortag:
$8.73
Offen:
$8.84
24-Stunden-Volumen:
543.66K
Relative Volume:
0.97
Marktkapitalisierung:
$501.19M
Einnahmen:
$9.68M
Nettoeinkommen (Verlust:
$-244.09M
KGV:
-2.0531
EPS:
-4.5346
Netto-Cashflow:
$-168.85M
1W Leistung:
+8.38%
1M Leistung:
+4.84%
6M Leistung:
-0.53%
1J Leistung:
-26.40%
1-Tages-Spanne:
$8.82
$9.315
1-Wochen-Bereich:
$8.3775
$9.315
52-Wochen-Spanne:
$4.32
$13.52
Prothena Corporation Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corporation Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
9.31 | 469.96M | 9.68M | -244.09M | -168.85M | -4.5346 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-04-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Oppenheimer | Outperform |
| 2021-05-26 | Eingeleitet | Citigroup | Buy |
| 2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
| 2018-04-05 | Bestätigt | Barclays | Overweight |
| 2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2017-09-29 | Bestätigt | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-12-21 | Eingeleitet | SunTrust | Buy |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-08-04 | Bestätigt | Barclays | Overweight |
| 2016-05-13 | Eingeleitet | Barclays | Overweight |
| 2016-02-19 | Bestätigt | Wedbush | Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Dow Update: Will Prothena Corporation plc benefit from rising consumer demandEntry Point & Low Risk High Reward Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Prothena stock rating on Parkinson’s data By Investing.com - Investing.com UK
Prothena Q4 earnings meet estimates, pipeline progress in focus - MSN
Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Prothena Corp plc stock gains spotlight as partners Roche and Bristol-Myers Squibb showcase key clin - AD HOC NEWS
Prothena Partners Present Data Supporting Next Generation Treatme - The National Law Review
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 - FinancialContent
Prothena Corp plc stock faces pressure amid biotech volatility and pipeline updates - AD HOC NEWS
Prothena authorizes up to $100 million share repurchase plan - MSN
Avoiding Lag: Real-Time Signals in (PRTA) Movement - Stock Traders Daily
Earnings Update: Will Prothena Corporation plc outperform its industry peers2026 Major Catalysts & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
History Review: Is Prothena Corporation plc attractive for institutional investors2026 Volume Leaders & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Biotech Headwinds Amid Pipeline Delays - AD HOC NEWS
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Headwinds Amid Biotech Volatility - AD HOC NEWS
Prothena Corporation plc $PRTA Stake Lessened by Prosight Management LP - MarketBeat
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Under Pressure Amid Biotech Volatility - AD HOC NEWS
Citizens reaffirms Prothena stock rating on Novo Nordisk milestone By Investing.com - Investing.com South Africa
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Pressure Amid Biotech Volatility - AD HOC NEWS
Prothena earns $50M milestone from Novo Nordisk for drug trial - Investing.com Nigeria
IPO Launch: Will Prothena Corporation plc outperform tech stocks2026 Movers & Weekly High Return Forecasts - baoquankhu1.vn
Prothena (NASDAQ:PRTA) Share Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Discipline and Rules-Based Execution in PRTA Response - Stock Traders Daily
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related t - PharmiWeb.com
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena Corporation Plc Receives $50 Million Clinical Milestone Payment From Novo Nordisk - marketscreener.com
Prothena earns $50M milestone from Novo Nordisk for drug trial By Investing.com - Investing.com South Africa
PRTA Earnings History & Surprises | EPS & Revenue Results | PROTHENA CORP PLC (NASDAQ:PRTA) - ChartMill
Is Prothena Corporation plc stock a dividend growth opportunity2025 Buyback Activity & Real-Time Buy Zone Alerts - Naître et grandir
Aug Reactions: Is Prothena Corporation plc attractive for institutional investors - baoquankhu1.vn
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution (NASDAQ:PRTA) - Seeking Alpha
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade - Finviz
Prothena (NASDAQ:PRTA) Shares Up 8.7%Still a Buy? - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of “Hold” by Analysts - Defense World
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Prothena Announces $100 Million Share Repurchase Program - The Globe and Mail
Prothena Corporation plc (PRTA) Stock Analysis: Navigating a 137% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Prothena authorizes $100 million share buyback program - Investing.com South Africa
Prothena Corporation plc announces an Equity Buyback for $100 million worth of its shares. - marketscreener.com
Prothena (NASDAQ: PRTA) okays $100M share buyback through 2026 - Stock Titan
Prothena Approves $100 Million Share Buyback Authorization - marketscreener.com
Prothena stock jumps on $100M share buyback authorization By Investing.com - Investing.com UK
Prothena Corporation plc (NASDAQ: PRTA) clears shelf to sell up to $200M in shares - Stock Titan
Prothena Announces up to $100 Million Share Repurchase Plan - The Joplin Globe
PROTHENA CORP PUBLIC LTD CO SEC 10-K Report - TradingView
Prothena (NASDAQ: PRTA) reshapes pipeline and cuts staff in 10-K - Stock Titan
Prothena Corporation plc authorizes a Buyback Plan. - marketscreener.com
Behavioral Patterns of PRTA and Institutional Flows - Stock Traders Daily
FY2026 EPS Estimates for Prothena Boosted by HC Wainwright - MarketBeat
Royal Bank Of Canada Increases Prothena (NASDAQ:PRTA) Price Target to $12.00 - Defense World
RBC Capital Raises Price Target for Prothena Corp (PRTA) to $12. - GuruFocus
Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):